<p>股市更广泛的基准指数不断创下新高，但 <strong>标普 500</strong> 指数的持续牛市主要受其最大组成部分的推动。这意味着仍然有许多可靠的股息支付股票看起来像是便宜货。</p>
<p><strong>强生</strong>(JNJ 0.12%)、<strong>同意房产</strong>(ADC 0.63%) 和 <strong>艾伯维</strong>(ABBV 0.22%) 的股票在最近的价格下提供诱人的股息收益率，到您准备退休时，它们可能会大幅提高股息支付。</p>
<h2>1. 强生</h2>
<p>去年，强生将其消费品部门分拆出来，该部门拥有许多大多数人们所熟知的传奇品牌。如今，强生专注于其更具利润性的制药和医疗技术业务。</p>
<p>该公司将于周三公布第二季度业绩，但我们已经看到分拆正在按计划进行。在第一季度，其医疗技术部门的销售额在调整不利的汇率变动后同比增长了 6.5%。</p>
<p>从某些指标来看，制药销售甚至更强劲，尽管有一个重要的警告。在不包括 COVID-19 疫苗销售的情况下，第一季度的制药销售同比增长了 8.3%。</p>
<p>股息计划很少有比强生更可靠的。今年 4 月，该公司连续第 62 年提高了每股季度股息。</p>
<p>在最近的股价下，它提供了 3.3% 的收益率，不断增长的制药销售有助于在未来几年迅速提高其股息。该公司最近推出的两款癌症药物 Tecvayli 和 Carvykti 在第一季度的销售额同比增长超过一倍。</p>
<h2>2. 同意房产</h2>
<p>同意房产是一家房地产投资信托 (REIT)，其租户主要经营抗衰退行业。它通常要求这些租户签订长期净租赁合同，使他们对建筑所有权的可变成本，如税收和维护负责。</p>
<p>通过这些长期租约内置的租金上涨机制，同意房产产生非常可靠的现金流。它从 2021 年开始将股息支付从季度改为月度。尽管自 2011 年以来，其年化股息支付一直稳步增长。</p>
<p>在最近的股价下，同意房产提供了 4.7% 的股息收益率。股价受到打压，因为较高的利率使其更昂贵地增加其物业组合，但现在看起来是一个明智的购买，因为该房地产投资信托在面临挑战的情况下仍处于良好位置。</p>
<p>在第一季度，它收购了遍布 22 个州的 31 个物业。今年 5 月，它将流动性位置扩大到超过 13 亿美元，以便继续扩大其版图。</p>
<h2>3. 艾伯维</h2>
<p>艾伯维起初是 <strong>雅培实验室</strong> 的制药部门，但在 2013 年分拆出来。自其成立以来持有艾伯维股票的投资者看到其股息支付飙升了 287%。在最近的价格下，股票提供了 3.6% 的收益率。</p>
<p>尽管最近过去的股息迅速增长，由于其前主导药物 Humira 销售下降，艾伯维的股价受到压力。在 2023 年失去专利保护市场独家销售权后，其销售额急剧下降。在 2024 年第一季度，美国 Humira 销售额同比下降了 39.9%，至 18 亿美元。</p>
<p>现在，国内 Humira 销售仅占总收入的 14%，抵消进一步下降应该更容易管理。多年来，艾伯维将其 Humira 利润进行了大量成功的再投资。</p>
<p>2019 年，艾伯维推出了两种新治疗药物--Skyrizi 和 Rinvoq--它们共同针对 Humira 开具处方的大多数病症，仅这两款药物在第一季度的销售额达到了 31 亿美元。</p>
<p>到 2027 年，艾伯维预计 Rinvoq 和 Skyrizi 的联合销售额将超过 270 亿美元 -- 但它们不是公司唯一的增长驱动力。将这家可靠的股息增长公司的股票加入您的投资组合可能会带来巨大的投资回报。</p>

同意房产

外服控股

强生

艾伯维

<p>三只高股息股票仍然看起来像是物美价廉的选择，它们分别是强生（Johnson & Johnson）、同意房产（Agree Realty）和艾伯维（AbbVie）。强生专注于制药和医疗技术业务，导致销售增长强劲，而同意房产通过长期净租赁提供可靠的现金流。艾伯维尽管其主要药物 Humira 的销售下滑，但由于其新药 Skryizi 和 Rinvoq 的成功，股息支付有显著增长。投资这些股票可能会在未来带来可观的回报</p>

<p>The broader stock market benchmarks keep reaching new heights, but the <strong>S&amp;P 500</strong> index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of reliable dividend-paying stocks that look like bargains.</p>
<div class="lb-trans"><p>股市更广泛的基准指数不断创下新高，但 <strong>标普 500</strong> 指数的持续牛市主要受其最大组成部分的推动。这意味着仍然有许多可靠的股息支付股票看起来像是便宜货。</p>
</div><p>Shares of <strong>Johnson &amp; Johnson</strong>(JNJ 0.12%), <strong>Agree Realty</strong>(ADC 0.63%), and <strong>AbbVie</strong>(ABBV 0.22%) offer enticing dividend yields at recent prices -- and they could raise their payouts much higher by the time you're ready to retire.</p>
<div class="lb-trans"><p><strong>强生</strong>(JNJ 0.12%)、<strong>同意房产</strong>(ADC 0.63%) 和 <strong>艾伯维</strong>(ABBV 0.22%) 的股票在最近的价格下提供诱人的股息收益率，到您准备退休时，它们可能会大幅提高股息支付。</p>
</div><h2>1. Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>1. 强生</h2>
</div><p>Last year, Johnson &amp; Johnson spun off its consumer goods division, which housed many of the legendary brands that most people associate with the company. These days, J&amp;J is focused on its more lucrative pharmaceutical and medical technology businesses.</p>
<div class="lb-trans"><p>去年，强生将其消费品部门分拆出来，该部门拥有许多大多数人们所熟知的传奇品牌。如今，强生专注于其更具利润性的制药和医疗技术业务。</p>
</div><p>The company reports second-quarter results on Wednesday, but we can already see the separation working as intended. In the first quarter, its medical technology unit's sales rose 6.5% year over year after adjusting for unfavorable changes in currency exchange rates.</p>
<div class="lb-trans"><p>该公司将于周三公布第二季度业绩，但我们已经看到分拆正在按计划进行。在第一季度，其医疗技术部门的销售额在调整不利的汇率变动后同比增长了 6.5%。</p>
</div><p>By some measures, pharmaceutical sales were even stronger -- though with an important caveat. Excluding its COVID-19 vaccine sales, first-quarter pharmaceutical sales rose 8.3% year over year.</p>
<div class="lb-trans"><p>从某些指标来看，制药销售甚至更强劲，尽管有一个重要的警告。在不包括 COVID-19 疫苗销售的情况下，第一季度的制药销售同比增长了 8.3%。</p>
</div><p>Dividend programs are rarely more reliable than Johnson &amp; Johnson's. In April, the company raised its quarterly payout for the 62nd consecutive year.</p>
<div class="lb-trans"><p>股息计划很少有比强生更可靠的。今年 4 月，该公司连续第 62 年提高了每股季度股息。</p>
</div><p>At recent share prices, it offers a 3.3% yield, and rising pharma sales could help it raise its payout rapidly in the years ahead. Two of the company's recently launched cancer drugs, Tecvayli and Carvykti, produced first-quarter sales that more than doubled year over year.</p>
<div class="lb-trans"><p>在最近的股价下，它提供了 3.3% 的收益率，不断增长的制药销售有助于在未来几年迅速提高其股息。该公司最近推出的两款癌症药物 Tecvayli 和 Carvykti 在第一季度的销售额同比增长超过一倍。</p>
</div><h2>2. Agree Realty</h2>
<div class="lb-trans"><h2>2. 同意房产</h2>
</div><p>Agree Realty is a real estate investment trust (REIT) with tenants that largely operate in recession-resistant industries. It generally insists those tenants sign long-term net leases that make them responsible for the variable costs associated with building ownership, such as taxes and maintenance.</p>
<div class="lb-trans"><p>同意房产是一家房地产投资信托 (REIT)，其租户主要经营抗衰退行业。它通常要求这些租户签订长期净租赁合同，使他们对建筑所有权的可变成本，如税收和维护负责。</p>
</div><p>With rent escalators built into those long-term leases, Agree Realty produces highly reliable cash flows. It switched from quarterly to monthly dividend payouts in 2021. Its annualized payout, though, has risen steadily since 2011.</p>
<div class="lb-trans"><p>通过这些长期租约内置的租金上涨机制，同意房产产生非常可靠的现金流。它从 2021 年开始将股息支付从季度改为月度。尽管自 2011 年以来，其年化股息支付一直稳步增长。</p>
</div><p>At recent share prices, Agree Realty offers a 4.7% dividend yield. The stock has been beaten down because higher interest rates make it more expensive to grow its portfolio of properties, but it looks like a smart buy now because the REIT is well-positioned to grow despite the challenge.</p>
<div class="lb-trans"><p>在最近的股价下，同意房产提供了 4.7% 的股息收益率。股价受到打压，因为较高的利率使其更昂贵地增加其物业组合，但现在看起来是一个明智的购买，因为该房地产投资信托在面临挑战的情况下仍处于良好位置。</p>
</div><p>In the first quarter, it acquired 31 properties spread across 22 states. In May, it expanded its liquidity position to more than $1.3 billion so it can keep on expanding its footprint.</p>
<div class="lb-trans"><p>在第一季度，它收购了遍布 22 个州的 31 个物业。今年 5 月，它将流动性位置扩大到超过 13 亿美元，以便继续扩大其版图。</p>
</div><h2>3. AbbVie</h2>
<div class="lb-trans"><h2>3. 艾伯维</h2>
</div><p>AbbVie began as the pharmaceutical division of <strong>Abbott Laboratories</strong>, but was spun off in 2013. Investors who have held on to AbbVie shares since their inception have seen their dividend payouts soar by 287%. At recent prices, the shares offer a 3.6% yield.</p>
<div class="lb-trans"><p>艾伯维起初是 <strong>雅培实验室</strong> 的制药部门，但在 2013 年分拆出来。自其成立以来持有艾伯维股票的投资者看到其股息支付飙升了 287%。在最近的价格下，股票提供了 3.6% 的收益率。</p>
</div><p>Despite rapid payout hikes in the recent past, AbbVie's share price has been under pressure due to declining sales of its former lead drug, Humira. After it lost patent-protected market exclusivity in 2023, its sales plunged. In 2024's first quarter, U.S. Humira sales fell 39.9% year over year to $1.8 billion.</p>
<div class="lb-trans"><p>尽管最近过去的股息迅速增长，由于其前主导药物 Humira 销售下降，艾伯维的股价受到压力。在 2023 年失去专利保护市场独家销售权后，其销售额急剧下降。在 2024 年第一季度，美国 Humira 销售额同比下降了 39.9%，至 18 亿美元。</p>
</div><p>Now that domestic Humira sales are responsible for just 14% of total revenue, offsetting further declines should be easier to manage. For years, AbbVie reinvested its Humira profits with a great deal of success.</p>
<div class="lb-trans"><p>现在，国内 Humira 销售仅占总收入的 14%，抵消进一步下降应该更容易管理。多年来，艾伯维将其 Humira 利润进行了大量成功的再投资。</p>
</div><p>In 2019, AbbVie launched two new treatments -- Skyrizi and Rinvoq -- that between them target most of the conditions that Humira is prescribed for, and their sales alone are offsetting the older drug's decline. Combined sales of Rinvoq and Skyrizi reached $3.1 billion in the first quarter.</p>
<div class="lb-trans"><p>2019 年，艾伯维推出了两种新治疗药物--Skyrizi 和 Rinvoq--它们共同针对 Humira 开具处方的大多数病症，仅这两款药物在第一季度的销售额达到了 31 亿美元。</p>
</div><p>In 2027, AbbVie expects combined Rinvoq and Skyrizi sales to exceed $27 billion -- but they're not the company's only growth drivers. Adding some shares of this reliable dividend grower to your portfolio could lead to huge returns on your investment down the road.</p>
<div class="lb-trans"><p>到 2027 年，艾伯维预计 Rinvoq 和 Skyrizi 的联合销售额将超过 270 亿美元 -- 但它们不是公司唯一的增长驱动力。将这家可靠的股息增长公司的股票加入您的投资组合可能会带来巨大的投资回报。</p>
</div>

3 只高收益股息股票仍然看起来很划算